EDITOR’S NOTE: We will be on a limited publication schedule later this month. Bulletins will be reduced the weeks of August 20-24 (we will publish M-W) and September 3-7 (we will publish W-F). There will be no bulletins the week of August 27-31. We will return to our normal publication schedule the week of September 10th.
This week, we provide top-five ranked VE data for our Medical Sector stocks. We take a look at our latest data on Snap Inc $SNAP and provide a free download link for our stock report on the company.
VALUATION WATCH: Overvalued stocks now make up 51.71% of our stocks assigned a valuation and 20.51% of those equities are calculated to be overvalued by 20% or more. Thirteen sectors are calculated to be overvalued.
ValuEngine Index Overview
| Index | Week Open | Friday PM | Change | % Change | YTD |
| DJIA | 25437.43 | 25342.53 | -94.9 | -0.37% | 2.47% |
| NASDAQ | 7809.54 | 7864.72 | 55.18 | 0.71% | 13.90% |
| RUSSELL 2000 | 1673.25 | 1693.53 | 20.28 | 1.21% | 10.34% |
| S&P 500 | 2840.29 | 2839.34 | -0.95 | -0.03% | 6.15% |
ValuEngine Market Overview
| Summary of VE Stock Universe | |
| Stocks Undervalued | 48.29% |
| Stocks Overvalued | 51.71% |
| Stocks Undervalued by 20% | 19.12% |
| Stocks Overvalued by 20% | 20.51% |
ValuEngine Sector Overview
| Sector | Change | MTD | YTD | Valuation | Last 12-MReturn | P/E Ratio |
| Computer and Technology | 0.10% | 2.73% | 8.69% | 16.07% overvalued | 26.77% | 31.97 |
| Aerospace | -0.34% | -1.19% | 7.33% | 14.47% overvalued | 18.45% | 26.69 |
| Retail-Wholesale | 0.20% | 1.04% | 6.51% | 10.24% overvalued | 26.68% | 24.28 |
| Medical | 0.03% | 0.40% | 14.71% | 10.22% overvalued | 42.88% | 30.18 |
| Multi-Sector Conglomerates | -0.26% | -0.31% | -1.52% | 8.31% overvalued | 7.47% | 20.66 |
| Business Services | 0.05% | 0.51% | 10.53% | 7.94% overvalued | 22.91% | 25.19 |
| Consumer Discretionary | 0.12% | 0.96% | 4.11% | 5.99% overvalued | 16.50% | 26.58 |
| Utilities | 0.52% | 1.20% | -3.43% | 4.62% overvalued | -3.10% | 20.01 |
| Finance | 0.02% | 0.19% | 2.53% | 2.80% overvalued | 8.01% | 17.70 |
| Consumer Staples | -0.07% | -0.78% | -1.42% | 2.70% overvalued | 10.62% | 24.53 |
| Auto-Tires-Trucks | 0.29% | 0.88% | -1.52% | 1.29% overvalued | 4.40% | 12.76 |
| Industrial Products | 0.24% | 0.57% | 4.10% | 1.07% overvalued | 17.25% | 25.35 |
| Transportation | 0.10% | 0.16% | -0.14% | 0.25% overvalued | 15.67% | 18.94 |
| Construction | -0.05% | -1.24% | 0.77% | 4.25% undervalued | 15.99% | 21.17 |
| Basic Materials | -0.36% | -1.27% | 3.62% | 8.19% undervalued | 2.56% | 20.98 |
| Oils-Energy | 0.42% | 0.19% | 8.95% | 11.82% undervalued | 17.98% | 25.31 |
Want to learn more about ValuEngine? Our methods? Our history?
Check out our video presentation HERE
Sector Talk–Medical
Below, we present the latest data on Medical stocks from our Professional Stock Analysis Service. Top- five lists are provided for each category. We applied some basic liquidity criteria–share price greater than $3 and average daily volume in excess of 100k shares.
Top-Five Medical Stocks–Short-Term Forecast Returns
| Ticker | Name | Mkt Price | Valuation (%) | Last 12-M Return (%) |
| IDRA | IDERA PHARMACT | 7.31 | 230.40% | 301.65% |
| ABUS | ARBUTUS BIOPH | 9.8 | 128.85% | 164.86% |
| FATE | FATE THERAPEUTC | 11.42 | 159.65% | 276.90% |
| XENE | XENON PHARMACT | 12.1 | 117.54% | 340.00% |
| ZGNX | ZOGENIX INC | 50.1 | 173.29% | 370.42% |
Top-Five Medical Stocks–Momentum
| Ticker | Name | Mkt Price | Valuation (%) | Last 12-M Return (%) |
| MDGL | MADRIGAL PHARMA | 236.1 | 300.00% | 1412.49% |
| MRTX | MIRATI THERAPTC | 58.65 | 155.20% | 1147.87% |
| ECYT | ENDOCYTE INC | 16.29 | 124.20% | 1106.67% |
| VKTX | VIKING THERAPTC | 9.89 | 117.49% | 957.87% |
| CDNA | CAREDX INC | 14.97 | 77.24% | 954.23% |
Top-Five Medical Stocks–Composite Score
| Ticker | Name | Mkt Price | Valuation (%) | Last 12-M Return (%) |
| NKTR | NEKTAR THERAP | 59.37 | -0.74% | 217.83% |
| BHC | BAUSCH HEALTH | 23.17 | -19.76% | 64.68% |
| THC | TENET HEALTH | 32.48 | -3.22% | 140.06% |
| ESRX | EXPRESS SCRIPTS | 81.82 | 0.39% | 33.69% |
| ENDP | ENDO INTL PLC | 15.83 | 17.36% | 99.37% |
Top-Five Medical Stocks–Most Overvalued
| Ticker | Name | Mkt Price | Valuation (%) | Last 12-M Return (%) |
| MDGL | MADRIGAL PHARMA | 236.1 | 300.00% | 1412.49% |
| IMMU | IMMUNOMEDICS | 23.29 | 300.00% | 184.02% |
| EIGR | EIGER BIOPHARMA | 9.85 | 300.00% | 27.92% |
| LJPC | LA JOLLA PHARMA | 24.465 | 286.56% | -23.09% |
| CASI | CASI PHARMACEUT | 7.3 | 246.84% | 637.37% |
Free Download for Readers
As a bonus to our Free Weekly Newsletter subscribers,
we are offering a FREE DOWNLOAD of one of our Stock Reports
Snap Inc. (SNAP) provides technology and social media services. The Company’s principal product Snapchat, is a camera application that helps people to communicate through short videos and images. Snap Inc. is headquartered in Venice, California.
VALUENGINE RECOMMENDATION: ValuEngine continues its HOLD recommendation on SNAP INC for 2018-08-09. Based on the information we have gathered and our resulting research, we feel that SNAP INC has the probability to ROUGHLY MATCH average market performance for the next year. The company exhibits ATTRACTIVE Company Size but UNATTRACTIVE Sharpe Ratio.
You can download a free copy of detailed report on Snap Inc. (SNAP) from the link below.
Read our Complete Rating and Forecast Report HERE
| ValuEngine Forecast | ||
| Target Price* |
Expected Return |
|
|---|---|---|
| 1-Month | 12.34 | 0.24% |
| 3-Month | 12.67 | 2.94% |
| 6-Month | 12.84 | 4.34% |
| 1-Year | 12.66 | 2.84% |
| 2-Year | 13.37 | 8.65% |
| 3-Year | 13.12 | 6.60% |
| Valuation & Rankings | |||
| Valuation | n/a | Valuation Rank(?) | n/a |
| 1-M Forecast Return | 0.24% | 1-M Forecast Return Rank | 68 |
| 12-M Return | -9.22% | Momentum Rank(?) | 21 |
| Sharpe Ratio | -0.96 | Sharpe Ratio Rank(?) | 6 |
| 5-Y Avg Annual Return | -44.18% | 5-Y Avg Annual Rtn Rank | 11 |
| Volatility | 45.88% | Volatility Rank(?) | 35 |
| Expected EPS Growth | 2.98% | EPS Growth Rank(?) | 23 |
| Market Cap (billions) | 8.15 | Size Rank | 86 |
| Trailing P/E Ratio | n/a | Trailing P/E Rank(?) | 17 |
| Forward P/E Ratio | n/a | Forward P/E Ratio Rank | n/a |
| PEG Ratio | 3.69 | PEG Ratio Rank | 9 |
| Price/Sales | 8.99 | Price/Sales Rank(?) | 13 |
| Market/Book | 4.09 | Market/Book Rank(?) | 33 |
| Beta | -2.57 | Beta Rank | 98 |
| Alpha | 0.25 | Alpha Rank | 87 |
ValuEngine.com is an Independent Research Provider (IRP), producing buy/hold/sell recommendations, target price, and valuations on over 5,000 US and Canadian equities every trading day.
Contact ValuEngine at (321) 325-0519 or support@valuengine.com
Visit www.ValuEngine.com for more information
ValuEngine Capital Management LLC is a Registered Investment Advisory (RIA) firm that trades client accounts using ValuEngine’s award-winning stock research.
Contact ValuEngine Capital at info@valuenginecapital.com
Visit www.ValuEngineCapital.com for more information
Steve Hach
Senior Editor
ValuEngine.com